Hiroyuki Sonoda
Kobe, 6590021, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodies.
Journal: Fluids and barriers of the CNS
Published: August 26, 2025
Adeno-associated virus expressing a blood-brain barrier-penetrating enzyme improves GM1 gangliosidosis in a preclinical model.
Journal: The Journal of clinical investigation
Published: March 04, 2024
Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
Journal: Molecular pharmaceutics
Published: October 20, 2023
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 10, 2023
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 16, 2023
Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro.
Journal: Frontiers in drug delivery
Published: October 28, 2022
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Journal: International journal of molecular sciences
Published: September 07, 2022
Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme.
Journal: Molecular genetics and metabolism reports
Published: August 17, 2022
Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis.
Journal: Pharmaceutics
Published: May 19, 2022
Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Published: April 14, 2022
Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 17, 2022
Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid.
Journal: Metabolic brain disease
Published: November 15, 2021
Last Updated: 09/26/2026